Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03188770
Other study ID # PRoVENT-iMIC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2017
Est. completion date January 29, 2019

Study information

Verified date July 2019
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this international, multicenter service review is to describe and compare ventilation management in patients at risk of acute respiratory distress syndrome (ARDS) versus patients not at risk and patients with established ARDS, and to ascertain whether certain ventilator settings and ventilation parameters are associated with pulmonary complications or development of ARDS after start of ventilation in patients in intensive care units (ICUs) in Asian countries.

Participating centers will include adult patients undergoing mechanical ventilation in the ICU during a 28-day period. Patients' data will be collected during the first 7 days in the ICU, or until ICU discharge. Follow up is until ICU discharge. The primary outcome includes two main ventilator settings, i.e., tidal volume and the level of positive end-expiratory pressure. Secondary endpoints are development of ARDS in patients without ARDS at the onset of mechanical ventilation, worsening of ARDS in patients with ARDS at the onset of mechanical ventilation, pulmonary infection, other pulmonary complications, need for tracheostomy, duration of ventilation, length of ICU stay and ICU mortality.


Description:

Rationale: scarce information exists on management of mechanical ventilation in intensive care unit (ICU) patients in low- and middle-income countries.

Objective:The primary objective is to describe and compare ventilation management in patients at risk of ARDS versus individuals not at risk, and patients with established ARDS, and to ascertain whether certain ventilation settings are associated with a higher incidence of developing ARDS in patients in ICUs in Asia. PRoVENT-iMIC secondary objectives are to determine the epidemiological characteristics and clinical outcomes of patients at risk of ARDS in ICUs in Asia according to the ventilation practice applied.

Primary hypothesis: a large proportion of patients at risk of ARDS in ICUs in Asia do not receive so-called protective ventilation, defined as tidal volume < 8 ml/kg predicted body weight and a level of positive end-expiratory pressure of at least 5 cm H2O.

Secondary hypothesis: in ICUs in Asia a large proportion of patients is at risk of ARDS, as stratified by a Lung Injury Prediction Score of ≥4.

Study design: an international multicenter service review focusing on ICUs in selected middle-income Asian countries.

Population: consecutive intubated and ventilated ICU patients.

Methods: Patients in participating ICUs will be screened daily during a 28-day period. A registry of limited demographic data will be compiled on all screened patients. Collection of ventilation characteristics is restricted to the first three days. The first seven days or up to death, whichever comes first, will be used for collection of patient demographics (on day of admission), development of ARDS and other pulmonary complications. All patients will be followed until ICU-discharge to determine length of stay in ICU and ICU mortality. The inclusion period will be flexible for participating centers and determined at a later stage together with the study-coordinator. Data will be coded by a patient identification number of which the code will be kept safe at the local sites. The data will be transcribed by local investigators onto an internet based electronic case report form (https://www.project-redcap.org).

Centers: about 60 Asian ICUs from ten countries are expected to participate in this international multicenter study. Each participating center will recruit ~ 50 patients.

Ethics Approval: The Oxford Tropical Research Ethical Committee has evaluated the study and considered it exempt from ethical review on the 1st of June 2017. National coordinators will be responsible for clarifying the need for ethics approval and applying for this where appropriate according to local policy. Centers will not be permitted to record data unless ethics approval or an equivalent waiver is in place.

Monitoring: Due to the observational nature of the study, a Data Safety and Monitoring Board is not necessary.

Sample Size Calculation: a formal sample size calculation was not performed, seen the largely descriptive character of this investigation. 3000 patients are expected to be enrolled in the study period, which will be sufficient to test the hypotheses.

Statistical Analysis: Patient characteristics will be compared and described by appropriate statistics. Student's t-test or Mann-Whitney U-tests are used to compare continuous variables and chi-squared tests are used for categorical variables. Data are expressed as means (SD), medians (interquartile range) and proportions as appropriate. Comparisons between and within groups are performed using one-way ANOVA and post-hoc analyses for continuous variables.

The primary analysis concerns the determination of (variation of) tidal volume and PEEP levels in patients without ARDS. These are compared between predefined patient groups: patients at no risk for ARDS, patients at risk for ARDS, patients with mild ARDS, and patients with moderate or severe ARDS.

To identify potential factors associated with outcome like development of ARDS, or worsening of ARDS, development of pulmonary complications, duration of ventilation, or death, univariate analyses are performed. A multivariate logistic regression model is used to identify independent risk factors. A stepwise approach is used to enter new terms into the model, with a limit of p < 0.2 to enter the terms. Time to event variables are analyzed using Cox regression and visualized by Kaplan-Meier.

Organization: The study is conducted by the PROtective VEntilation Network (PROVENet). National co-ordinators will lead the project within individual nations and identify participating hospitals, translate study paperwork, distribute study paperwork and ensure necessary regulatory approvals are in place. They provide assistance to the participating clinical sites in trial management, record keeping and data management. Local coordinators in each site will supervise data collection and ensure adherence to Good Clinical Practice during the trial.


Recruitment information / eligibility

Status Completed
Enrollment 1315
Est. completion date January 29, 2019
Est. primary completion date November 29, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Admitted to an ICU participating in this study

- Intubated in the ICU, or in the emergency room, general ward, or operation room before the present ICU admission

Exclusion Criteria:

- Age < 18 years

- Patients under invasive mechanical ventilation previous to the 28-day period of inclusion

- Patients transferred from another hospital under invasive mechanical ventilation

- Receiving only non-invasive ventilation (i.e., patient never received invasive ventilation during the present admission)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Bangladesh Chittagong Medical College Hospital Chittagong
Bangladesh Bangabandhu Sheikh Mujib Medical University Dhaka
Bangladesh BIRDEM General Hospital Dhaka
Bangladesh Dhaka Medical College Hospital Dhaka
Bangladesh Rajshahi Medical College Hospital Rajshahi
Bangladesh Sylhet MAG Osmani Medical College Hospital Sylhet
India St. John's Medical College Bangalore
India Bharati Vidyapeeth Medical College Pune
India Ispat General Hospital Raurkela Odisha
Iran, Islamic Republic of Masih Daneshvari Hospital Tehran
Iran, Islamic Republic of Modarres Hospital Tehran
Iran, Islamic Republic of Pars Hospital Tehran
Malaysia Monash University Johor Bahru
Malaysia Hospital Kuala Lumpur Kuala Lumpur
Malaysia Mohamad Irfan Bin Othman Jailani Kuala Lumpur
Malaysia International Islamic University Medical Center Kuantan
Maldives Indira Gandhi Memorial Hospital Malè
Nepal Patan Academy of Health Sciences Katmandou
Pakistan Allied Hospital Faisalabad
Pakistan PIMS Islamabad
Pakistan Shifa International Hospital Islamabad
Pakistan Aga Khan University Hospital MICU Karachi
Pakistan Aga Khan University SICU Karachi
Pakistan Patel Hospital Karachi
Pakistan Doctor's Hospital Lahore
Pakistan National Hospital and Medical Center Lahore
Pakistan Peoples Medical College Hospital Nawabshah
Pakistan North West General Hospital Peshawar
Sri Lanka Batticaloa Base Hospital Batticaloa
Sri Lanka Colombo South Teaching Hospital MICU Colombo
Sri Lanka Colombo South Teaching Hospital SICU Colombo
Sri Lanka Lanka Hospital Colombo
Sri Lanka National Hospital Sri Lanka MICU Colombo
Sri Lanka National Hospital Sri Lanka SICU Colombo
Sri Lanka Sri Jayawardenepura CTICU Colombo
Sri Lanka Sri Jayewardenepura General Hospital GICU Colombo
Sri Lanka Karapitiya Teaching Hospital Galle
Sri Lanka Jaffna Teaching Hospital Jaffna
Sri Lanka Puttlam Hospital Puttalam
Thailand Chulalongkorn University Hospital Bangkok
Thailand Hospital for Tropical Diseases, Mahidol University Bangkok
Thailand Ramathibodi Hospital Bangkok
Thailand Sriraj Hospital Bangkok
Thailand Vajira Hospital Bangkok
Thailand Chiang Mai Hospital Surgical ICU Chiang Mai
Thailand Chiang Mai Medical ICU Chiang Mai
Thailand Nakornping Hospital Chiang Mai
Thailand Prince of Songkla University Hat Yai
Thailand Srinakharinwirot University Ongkharak
Vietnam National Hospital for Tropical Diseases Hanoi
Vietnam Oxford University Clinical Research Unit Ho Chi Minh City

Sponsors (3)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Hospital Israelita Albert Einstein, Mahidol Oxford Tropical Medicine Research Unit

Countries where clinical trial is conducted

Bangladesh,  India,  Iran, Islamic Republic of,  Malaysia,  Maldives,  Nepal,  Pakistan,  Sri Lanka,  Thailand,  Vietnam, 

References & Publications (2)

Neto AS, Barbas CSV, Simonis FD, Artigas-Raventós A, Canet J, Determann RM, Anstey J, Hedenstierna G, Hemmes SNT, Hermans G, Hiesmayr M, Hollmann MW, Jaber S, Martin-Loeches I, Mills GH, Pearse RM, Putensen C, Schmid W, Severgnini P, Smith R, Treschan TA, — View Citation

Serpa Neto A, Cardoso SO, Manetta JA, Pereira VG, Espósito DC, Pasqualucci Mde O, Damasceno MC, Schultz MJ. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. JAMA. 2012 Oct 24;308(16):1651-9. doi: 10.1001/jama.2012.13730. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Tidal volume size Tidal volume size in milliliters per kilogram of predicted body weight Day 1 to Day 3 from initiation of mechanical ventilation
Primary Positive end-expiratory pressure Pressure in cm of water Day 1 to Day 3 from initiation of mechanical ventilation
Secondary Patients at risk of ARDS Risk of ARDS is stratified using the Lung Injury Prediction Score. On the date of inclusion
Secondary Inspired Oxygen Concentration expressed as fraction of inspired oxygen Day 1 to Day 3 from initiation of mechanical ventilation
Secondary Plateau pressure Pressure in cm of water Day 1 to Day 3 from initiation of mechanical ventilation
Secondary Peak pressure Peak away pressure in cm of water Day 1 to Day 3 from initiation of mechanical ventilation
Secondary Driving pressure pressure in cm of water Day 1 to Day 3 from initiation of mechanical ventilation
Secondary Respiratory Rate in breaths per minute Day 1 to Day 3 from initiation of mechanical ventilation
Secondary Minute Volume expressed as liters per minute Day 1 to Day 3 from initiation of mechanical ventilation
Secondary Development of ARDS Development of ARDS in patients without ARDS at the onset of mechanical ventilation. Patients are defined as having ARDS if they meet the Berlin criteria for ARDS From date of inclusion until the date of first documented development of ARDS or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days
Secondary Worsening of ARDS Defined as any worsening in the degree of severity according to Berlin criteria. From date of inclusion until the date of first documented worsening of ARDS or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days
Secondary Pulmonary infection defined as need of new antibiotics in the presence of new or changed lung opacities on chest X-ray and/or new or changed sputum plus at least one of the following criteria: 1) temperature > 38.3 ºC; or 2) WBC count > 12,000 From date of inclusion until the date of first documented pulmonary complication or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days
Secondary Other Pulmonary complications pneumothorax, pleural effusions, cardiogenic pulmonary edema, new pulmonary infiltrates, and atelectasis From date of inclusion until the date of first documented pulmonary complication or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days
Secondary Need for tracheostomy Need for tracheostomy during ICU stay From date of inclusion until the date of first documented tracheostomy procedure or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days
Secondary Length of stay in ICU Time between admission and discharge or death Until day 35 from study initiation
Secondary All-cause ICU mortality Any death during ICU stay Until day 35 from study initiation
Secondary Duration of mechanical ventilation time between orotracheal intubation and successful extubation;note: in case of intermittent MV via a tracheostomy, every day a patient needs MV counts as one extra day of MV, irrespective of duration of MV that specific day; in case of non-invasive ventilation (CPAP and/or BIPAP), the duration will be assessed separated from the assessment of invasive mechanical ventilation. Until day 35 from study initiation
See also
  Status Clinical Trial Phase
Completed NCT05921656 - Construction and Evaluation of Airway Leakage Risk Model of Patients With Endotracheal Tube
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Withdrawn NCT04288076 - The Brain and Lung Interaction (BALI) Study N/A
Completed NCT03031860 - Semi-quantitative Cough Strength Score (SCSS) N/A
Completed NCT02312869 - Local Assessment of Management of Burn Patients N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed NCT01885442 - TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients N/A
Completed NCT01204281 - Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients Phase 4
Terminated NCT01059929 - Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU) Phase 4
Completed NCT00824239 - Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients Phase 3
Completed NCT00529347 - Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern Phase 1
Unknown status NCT00260676 - Protective Ventilatory Strategy in Potential Organ Donors Phase 3
Terminated NCT00205517 - Sedation and Psychopharmacology in Critical Care N/A
Completed NCT03281785 - Ultrasound of Diaphragmatic Musculature in Mechanically Ventilated Patients. N/A
Recruiting NCT04110613 - RCT: Early Feeding After PEG Placement N/A
Completed NCT04410783 - The Emergency Department Sedation Pilot Trial N/A
Recruiting NCT04821453 - NAVA vs. CMV Crossover in Severe BPD N/A
Completed NCT03930147 - Ventilation With ASV Mode in Children N/A
Recruiting NCT05029167 - REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study) N/A
Recruiting NCT04849039 - Lung Microbiota and VAP Development (PULMIVAP)